Application to the patient population. In theory, allele-specific targeting using TALE could potentially cover 100% of the patient population. The use of multiple TALEs may be capable of covering 100% of the patient population, allowing flexibility for either allelic silencing, pending SNP allele analysis, or CAG collapse in regards to potential gene therapies. HTT, Huntingtin gene. Adapted from Kay et al. (22).